<DOC>
	<DOCNO>NCT01769911</DOCNO>
	<brief_summary>This clinical trial study genetically modify peripheral blood stem cell transplant treat patient HIV-associated non-Hodgkin Hodgkin lymphoma . Giving chemotherapy peripheral stem cell transplant stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood store . More chemotherapy radiation therapy give prepare bone marrow stem cell transplant . Laboratory-treated stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy</brief_summary>
	<brief_title>Genetically Modified Peripheral Blood Stem Cell Transplant Treating Patients With HIV-Associated Non-Hodgkin Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety feasibility infuse gene-modified , human immunodeficiency virus ( HIV ) -protected hematopoietic stem cell ( HSC ) high-dose chemotherapy treatment acquire immunodeficiency syndrome ( AIDS ) -related lymphoma . II . To determine dose carmustine ( BCNU ) combination O^6-benzylguanine ( O6BG ) result selection vivo gene-modified HIV-resistant cell . III . To estimate effect HIV infection presence HIV-resistant blood cell measure genetic marking vector sequence antiviral treatment interruption . SECONDARY OBJECTIVES : I . Evaluate molecular clonal composition gene-modified cell hematopoietic cell transplant ( HCT ) . II . Evaluate molecular clonal composition gene-modified cell O6BG/BCNU . III . Determine correlation level O6-methylguanine- methyltransferase ( MGMT ) ( P140K ) mark toxicity response . IV . Characterize toxicity associate vivo selection . V. Determine efficacy procedure treatment lymphoma : defined time disease progression , progression-free survival , treatment-related mortality , time neutrophil platelet recovery , incidence infection . TERTIARY OBJECTIVES : I . Effect procedure latent HIV reservoir . II . Effect procedure HIV-specific immune reconstitution . OUTLINE : CONDITIONING : Patients receive carmustine intravenously ( IV ) 3 hour day -7 , cytarabine IV 2 hour twice daily ( BID ) etoposide IV 2 hour BID day -6 -3 , melphalan IV 30 minute day -2 . TRANSPLANTATION : Patients receive autologous PBSC infusion and/or infusion autologous transduce hematopoietic cell day 0 . Beginning 28-120 day later , patient eligible vivo selection detection gene-marked cell receive O6-benzylguanine IV 1 hour carmustine IV 3 hour day 14 , 28 , monthly completion therapy . Patients achieve &gt; 10 % gene mark CD4 count &gt; = 500 cells/uL receive 2 course structure treatment interruption without undergo vivo selection . After completion study treatment , patient follow periodically 15 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Lymphoma , AIDS-Related</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>HIV seropositive Antiretroviral treatment least one month , define multidrug regimen ( exclude azacitidine [ AZT ] ) HIV plasma viral load decrease 1.5 log viral load &lt; 5000 copies/ml NonHodgkin Hodgkin lymphoma without active central nervous system ( CNS ) involvement associate poor prognosis medical therapy alone autologous peripheral blood stem cell ( PBSC ) transplant indicate : Hodgkin 's lymphoma beyond first remission ; first partial remission ; induction failure subsequent response salvage therapy NonHodgkin 's Lymphoma beyond first remission : first partial remission ; induction failure subsequent response salvage therapy Chemotherapy responsive disease Karnofsky performance score &gt; = 70 % Subjects must agree use effective contraception enrollment completion study Female subject : child bear potential , must negative serum urine pregnancy test within 7 day treatment Subjects must prophylactic regimen Pneumocystis carinii pneumonia , agree begin treatment , cluster differentiation ( CD ) 4 count = &lt; 200 Ability understand willingness sign write informed consent document Serum creatinine &gt; 2 time upper limit normal Serum bilirubin great 3 time upper limit normal , unless determine result primary hematologic malignancy attribute Gilbert 's syndrome Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 3 time upper limit normal , unless determine result primary hematologic malignancy attribute Gilbert 's syndrome Forced vital capacity ( FVC ) , forced expiratory volume 1 second ( FEV1 ) diffusion capacity lung carbon monoxide ( DLCO ) parameter &lt; 60 % predict ( correct hemoglobin ) Left ventricular ejection fraction ( LVEF ) &lt; 50 % coronary artery disease require treatment Active infection require systemic antibiotic therapy antibacterial , antifungal , antiviral agent ( exclude HIV ) Patients hepatitis C virus ( HCV ) antibody positive hepatitis B virus ( HBV ) surface antigen positive must free clinical evidence cirrhosis would otherwise make ineligible HCT , determine Principal Investigator ( P.I . ) consultation Gastrointestinal Service ; patient HBV ongoing evidence viral replication may require therapy prior receive highdose chemotherapy Positive serology Toxoplasma gondii AND require treatment evidence active infection Malignancy lymphoma , unless 1 ) complete remission 5 year last treatment ) , 2 ) cervical/anal squamous cell carcinoma situ 3 ) superficial basal cell squamous cell cancer skin History HIVassociated encephalopathy ; dementia kind ; seizure past 12 month ; perceive inability directly provide inform consent ( Note : Consent may obtain mean legal guardian ) A medical history noncompliance highly active antiretroviral therapy ( HAART ) medical therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>